To assess the long-term risk of developing cancer among heart transplant recipients compared to the Canadian general population, we carried out a retrospective cohort study of 1703 patients who received a heart transplant between 1981 and 1998, identified from the Canadian Organ Replacement Register database. Vital status and cancer incidence were determined through record linkage to the Canadian Mortality Database and Canadian Cancer Registry. Cancer incidence rates among heart transplant patients were compared to those of the general population. The observed number of incident cancers was 160 with 58.9 expected in the general population (SIR = 2.7, 95% CI = 2.3, 3.2). The highest ratios were for non-Hodgkin's lymphoma (NHL) (SIR = 22.7, 95% CI = 17.3, 29.3), oral cancer (SIR = 4.3, 95% CI = 2.1, 8.0) and lung cancer (SIR = 2.0, 95% CI = 1.2, 3.0). Compared to the general population, SIRs for NHL were particularly elevated in the first year posttransplant during more recent calendar periods, and among younger patients. Within the heart transplant cohort, overall cancer risks increased with age, and the 15-year cumulative incidence of all cancers was estimated to be 17%. There is an excess of incident cases of cancer among heart transplant recipients. The relative excesses are most marked for NHL, oral and lung cancer.
Introduction
Heart or cardiac transplantation is a well-established procedure to treat patients with end-stage heart disease or severe coronary artery disease (1) . In the United States, the number of people living with a functioning heart allograft at year-end increased from 13 829 in 1997 to 18 018 in 2005 (2) . As of June 15, 2007, 1- (3) . In Canada, patient and graft survival have continued to increase in the last decade (4) . Heart transplants are now the third most common organ transplant operation with 1633 heart transplants between 1997 and 2006 (5) . One (6, 7) . (8, 9) . Posttransplant malignancies have been shown to occur in over 15% of patients with longterm follow-up (10) (11) (12) . The most commonly reported cancers are skin cancer and posttransplant lymphoproliferative disorders (PTLD) (13) . Some studies have also shown that the risk of lung cancer was increased among cardiactransplant patients resulting in a poor prognosis (14, 15) . Immunosuppressive drugs have been recognized as the major factor contributing to the increased incidence of cancer in transplant recipients (16) .
It is known that the improvement in survival of patients following heart transplantation is hampered by a high incidence of cancer
There have been few large studies of the incidence of cancer following heart transplantation. Most published studies have relied on patient data collected from a single study centre, and the number of patients has been relatively small (10, 12, 17, 18) . Therefore, these studies are not able to characterize precisely the long-term risks of developing rarer forms of cancer, and moreover, there may be constraints in identifying incident cancers among those who have moved to other regions. Recently, a multi-centre Italian study found increased risks of cancer among a cohort of 724 patients following heart (n = 682) or lung (n = 42) transplantation (19) . The 
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Ascertainment of health outcomes
The Generalized Record Linkage System (GRLS) (23) 
Statistical analysis
The incidence rates of cancers in heart transplant patients were compared with those in the Canadian general population using the standardized incidence ratio ( (1981-1989, 1990-1992, 1993-1995 and 1996-1998) . This required tabulating the PY of follow-up within each of these strata, which was done using the DATAB module in the Epicure software program (30) .
SIR). The SIR is the ratio of observed to expected incident cancer, where 'expected' refers to the number expected to occur if heart transplant patients were subject to the same cancer risk as the general population. The Poisson distribution was used to determine 95% confidence intervals (CI) for the SIRs (29). To adjust for differences in the age and sex distribution between the two populations, as well as changes in cancer in
Internal cohort comparisons were made using the Cox regression model to evaluate the effects of several covariates simultaneously on the long-term risk of developing cancer. Age, sex and transplant year were used to examine the independent effects on the risk of all cancers and non-Hodgkin's lymphoma (NHL) after heart transplantation. Additionally, competing risks survival methodology, based on formulae presented by Gooley et al. (31), were applied to estimate the cumulative incidence of developing certain cancers after transplantation. Following this method, persons who die or develop another form of cancer are no longer at risk of developing the index cancer (as a primary cancer). This differs from the complement of the Kaplan-Meier survival estimator which treats patients who die as censored and hence implicitly assumes that they remain at risk to develop the index cancer in the future (32).
Heart Transplant and Cancer Incidence
Finally, as a subanalysis and as a follow-up to our previous work (33, 34) Heart Transplant and Cancer Incidence 
